Clinical Trials
17 trialsNCT03530397 2026-05-19
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Active not recruiting
NCT06564623 2026-05-08
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT07476326 2026-04-03
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
NCT03293784 2026-03-30
TICIMEL
Institut Claudius Regaud
Phase 1 Completed
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting
NCT06934616 2025-04-30
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
Genor Biopharma Co., Ltd.
Phase 1 Not yet recruiting
NCT06258304 2025-04-10
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
GigaGen, Inc.
Phase 1 Recruiting
NCT05235438 2023-05-24
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT03507699 2023-04-18
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Sheba Medical Center
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT00836407 2020-02-24
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02705482 2019-08-26
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT01216436 2015-05-25
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Duke University
Phase 1 Terminated
NCT00028431 2014-05-22
Novel Adjuvants for Peptide-Based Melanoma Vaccines
University of Southern California
Phase 1 Completed